fig3

Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approaches

Figure 3. Mechanisms of AR protein degradation. (A) PROTACs recruit the AR protein and E3 Ub ligase complex into close proximity, facilitating ubiquitination and subsequent proteasomal degradation; (B) SARDs bind directly to AR and promote its degradation through the proteasome, reducing AR-mediated signaling; (C) Hydrophobic tagging involves attaching a lipophilic moiety to the AR protein, causing it to fold improperly and be recognized by the cell’s quality control machinery, ultimately targeting it for Ub-proteasome-mediated degradation. AR: Androgen receptor; PROTACs: proteolysis-targeting chimeras; Ub: ubiquitin; SARDs: selective androgen receptor degraders.

Cancer Drug Resistance
ISSN 2578-532X (Online)

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/